Read as much as you want on BostonGlobe.com, anywhere and anytime, for just 99¢.

Map Pharmaceuticals

Continue reading below

Regulators did not reject Map’s inhalable migraine drug because of safety or effectiveness and don’t want new studies, CEO Tim Nelson said - it was about manufacturing issues. Levadex is an inhaled form of a 60-year-old migraine drug that’s injected. Map, of Mountain View, Calif., seeks approval for its use in patients with 15 or fewer migraines a month; it would be Map’s first marketed product. The shares’ drop was a “knee-jerk reaction,’’ said Liana Moussatos, at Wedbush Securities. “It sounds like there are just manufacturing issues, no clinical safety issues.’’

Loading comments...

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week